Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin efficacy prediction model using genetic variation and serum metabolites in newly diagnosed type 2 diabetes
ChiCTR1900028227Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: blood glucose level, glycosylated hemoglobin and 2 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900028227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028227.